0001209191-21-014549.txt : 20210225
0001209191-21-014549.hdr.sgml : 20210225
20210225210522
ACCESSION NUMBER: 0001209191-21-014549
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210223
FILED AS OF DATE: 20210225
DATE AS OF CHANGE: 20210225
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Menzaghi Frederique Ph.D.
CENTRAL INDEX KEY: 0001597152
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36279
FILM NUMBER: 21683268
MAIL ADDRESS:
STREET 1: C/O CARA THERAPEUTICS, INC.
STREET 2: 1 PARROTT DRIVE
CITY: SHELTON
STATE: CT
ZIP: 06484
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001346830
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4 STAMFORD PLAZA
STREET 2: 107 ELM STREET 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 203-406-3700
MAIL ADDRESS:
STREET 1: 4 STAMFORD PLAZA
STREET 2: 107 ELM STREET 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
FORMER COMPANY:
FORMER CONFORMED NAME: Cara Therapeutics Inc
DATE OF NAME CHANGE: 20051213
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-23
0
0001346830
Cara Therapeutics, Inc.
CARA
0001597152
Menzaghi Frederique Ph.D.
C/O CARA THERAPEUTICS, INC.
4 STAMFORD PLAZA, 107 ELM ST, 9TH FLOOR
STAMFORD
CT
06902
0
1
0
0
Chief Scientific Off,SVP-R&D
Common Stock
2021-02-23
4
A
0
8000
0.00
A
117680
D
Common Stock
2021-02-25
4
S
0
5003
19.33
D
112677
D
Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on February 23, 2021. The vested shares represents the last possible vesting event of the total number of shares subject to the award.
This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person.
/s/Darren DeStefano, Attorney-in-Fact
2021-02-25